Evidence map›Paper›PMID 29489750›Full record

ArticleNature2018

The SMAD2/3 interactome reveals that TGFβ controls m

Alessandro Bertero, Stephanie Brown, Pedro Madrigal, Anna Osnato, Daniel Ortmann, Loukia Yiangou, Juned Kadiwala, Nina C Hubner, Igor Ruiz de Los Mozos, Christoph Sadée and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 246 papers.

0numbers the graph read from it
0cells of the map it votes in
246citing papers in PubMed
21.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

246 citing papers in PubMed, 390 citations in OpenAlex.

  1. NAR cancer · 2026
    Article
  2. Beyond mBiomedicines · 2026
    Review
  3. The role of mNaunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  4. mNature reviews. Neuroscience · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Targeting intracellular mRNA mJournal of advanced research · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. mCancer gene therapy · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. NBiomolecules · 2026
    Review
  18. Article
  19. Article
  20. Review

186 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Commented on by
    m2018
5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Alessandro BerteroWellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory and Department of Surgery, University of Cambridge, Cambridge CB2 0SZ, UK.
Stephanie BrownWellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory and Department of Surgery, University of Cambridge, Cambridge CB2 0SZ, UK.
Pedro MadrigalWellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory and Department of Surgery, University of Cambridge, Cambridge CB2 0SZ, UK.
Anna OsnatoWellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory and Department of Surgery, University of Cambridge, Cambridge CB2 0SZ, UK.
Daniel OrtmannWellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory and Department of Surgery, University of Cambridge, Cambridge CB2 0SZ, UK.
Loukia YiangouWellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory and Department of Surgery, University of Cambridge, Cambridge CB2 0SZ, UK.
Juned KadiwalaWellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory and Department of Surgery, University of Cambridge, Cambridge CB2 0SZ, UK.
Nina C HubnerDepartment of Molecular Biology, Radboud University, Nijmegen 6525GA, The Netherlands.
Igor Ruiz de Los MozosFrancis Crick Institute and Department of Molecular Neuroscience, University College London, London NW1 1AT, UK.
Christoph SadéeFrancis Crick Institute and Department of Molecular Neuroscience, University College London, London NW1 1AT, UK.
An-Sofie LenaertsWellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory and Department of Surgery, University of Cambridge, Cambridge CB2 0SZ, UK.
Shota NakanohWellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory and Department of Surgery, University of Cambridge, Cambridge CB2 0SZ, UK.
Rodrigo GrandyWellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory and Department of Surgery, University of Cambridge, Cambridge CB2 0SZ, UK.
Edward FarnellDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Jernej UleFrancis Crick Institute and Department of Molecular Neuroscience, University College London, London NW1 1AT, UK.
Hendrik G StunnenbergDepartment of Molecular Biology, Radboud University, Nijmegen 6525GA, The Netherlands.
Sasha MendjanWellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory and Department of Surgery, University of Cambridge, Cambridge CB2 0SZ, UK.
Ludovic VallierWellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory and Department of Surgery, University of Cambridge, Cambridge CB2 0SZ, UK.
Wellcome/MRC Cambridge Stem Cell Institute · GBUniversity of Cambridge · GBUniversity College London · GBRadboud University Nijmegen · NLWellcome Sanger Institute · GB

Funding

European Research Council 281335Medical Research Council MC_PC_12009Medical Research Council MC_U105185858Wellcome Trust
6 · The paper itself

Abstract

The TGFβ pathway has essential roles in embryonic development, organ homeostasis, tissue repair and disease. These diverse effects are mediated through the intracellular effectors SMAD2 and SMAD3 (hereafter SMAD2/3), whose canonical function is to control the activity of target genes by interacting with transcriptional regulators. Therefore, a complete description of the factors that interact with SMAD2/3 in a given cell type would have broad implications for many areas of cell biology. Here we describe the interactome of SMAD2/3 in human pluripotent stem cells. This analysis reveals that SMAD2/3 is involved in multiple molecular processes in addition to its role in transcription. In particular, we identify a functional interaction with the METTL3-METTL14-WTAP complex, which mediates the conversion of adenosine to N

Indexed as

ActivinsAdenosineAnimalsCell Cycle ProteinsCell DifferentiationEpigenesis, GeneticHumansMethylationMethyltransferasesMultiprotein ComplexesNanog Homeobox ProteinNodal ProteinNuclear ProteinsPluripotent Stem CellsProtein BindingRNA, Messenger6-methyladenine mRNA methyltransferaseActivinsAdenosineCell Cycle ProteinsMethyltransferasesMETTL14 protein, humanMETTL3 protein, humanMultiprotein ComplexesNanog Homeobox ProteinN-methyladenosineNodal ProteinNuclear ProteinsRNA, MessengerRNA Splicing FactorsSmad2 ProteinSMAD2 protein, humanSmad3 ProteinSMAD3 protein, humanTransforming Growth Factor betaWTAP protein, human

Identifiers

PMID29489750
PMCPMC5951268
OpenAlexW2788604588

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.